Literature DB >> 7995011

Effects of lisinopril and nitroglycerin on blood pressure early after myocardial infarction: the GISSI-3 pilot study.

R Latini1, F Avanzini, A De Nicolao, M Rocchetti.   

Abstract

OBJECTIVES: To evaluate the safety in terms of hypotensive action of nitroglycerin and lisinopril started early after myocardial infarction. PATIENTS AND METHODS: One thousand five hundred twenty-six patients with suspected myocardial infarction were randomized by 174 centers within 24 hours from the onset of symptoms to receive oral lisinopril (5 then 10 mg/day), nitroglycerin (intravenous infusion during the first 24 hours, then 10 mg/day transdermal), or neither.
RESULTS: Systolic blood pressure, intensively monitored during the first 72 hours, decreased sharply by 11 mm Hg during the first 2 hours, then more slowly to an average value of 120 mm Hg. Nitroglycerin lowered systolic blood pressure during the first 24 hours by 2.7 mm Hg versus control subjects, and it was similar to control subjects from 24 hours. Lisinopril reduced systolic blood pressure by 4.2 mm Hg over 72 hours compared with control subjects. Persistent hypotension was significantly more frequent in the lisinopril group (21.4%) than in the nitroglycerin group (10.9%) or control group (9.8%), but absolute numbers of deaths in patients with persistent hypotension were almost identical.
CONCLUSIONS: Lisinopril and nitroglycerin are both safe and effective in reducing blood pressure in the first day after myocardial infarction. However, the effect is lost thereafter with transdermal nitroglycerin, but persists with lisinopril.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7995011     DOI: 10.1038/clpt.1994.194

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  3 in total

Review 1.  Lisinopril. A review of its pharmacology and clinical efficacy in the early management of acute myocardial infarction.

Authors:  K L Goa; J A Balfour; G Zuanetti
Journal:  Drugs       Date:  1996-10       Impact factor: 9.546

Review 2.  A risk-benefit assessment of ACE inhibitor therapy post-myocardial infarction.

Authors:  C Borghi; E Ambrosioni
Journal:  Drug Saf       Date:  1996-05       Impact factor: 5.606

Review 3.  Clinical aspects of ACE inhibition in patients with acute myocardial infarction.

Authors:  C Borghi; E Ambrosioni
Journal:  Cardiovasc Drugs Ther       Date:  1996-11       Impact factor: 3.727

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.